Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 06 Mar 2023
USA: The syrup drug Diethylene glycol (DEG), a drug commonly used to prevent infections, is the cause of kidney disease...
Read Full NewsAnemia Correction Before Colorectal Surgery Yields No Postoperative Gains
Mease discussed his hopes for the new approval's impact on the fibromyalgia field.
The rheumatology month in review emphasizes new approvals and the latest comparative research.
Q3 2025 saw several new first targeted therapies for rare and more individualized indications in a number of fields.
Q3 2025 saw a number of exciting approvals and data on promising therapies in development.
Prajapati discussed the impact of the expanded approval of guselkumab to pediatric PsO and psoriatic arthritis.
Sonelokimab meets ACR50 primary endpoint in a phase 2 trial.
1.
For patients with clear cell renal cell carcinoma, a new PET agent allows for same-day imaging.
2.
'Full House' Star's Cancer; Fluoride Fears Go Mainstream; Florida Doctor Arrested
3.
AI Model as Effective as Radiologists in Detecting Prostate Cancer on MRI
4.
Eight Doctors Killed in Brazil's Horrifying Plane Crash
5.
Study: For predicting breast cancer, AI performs better than traditional risk models.
1.
Deciphering FFR: A Comprehensive Guide to Understanding Its Meaning
2.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
3.
Genetic Screening: A Game Changer in Cancer Prevention
4.
Revolutionizing Cancer Care with Fulphila: A New Hope for Patients
5.
Exploring Digital Cognitive Stimulation for Elderly Breast Cancer Patients
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Key Takeaways from The CROWN Trial For ALK + NSCLC Patients with CNS Diseases
2.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VI
5.
Current Scenario of Blood Cancer- Further Discussion on Genomic Testing & Advancement in Diagnosis and Treatment
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge